Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2020, with a specific reporting date of April 14, 2020. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| April 9, 2020 | Ordinary Shares (25p each) | £15.3297 | 1,736 shares | London Stock Exchange (XLON) |
Note: The total volume of 1,736 shares is the aggregate of six individual transactions listed in the filing.
Material Changes
The filing does not report material changes to the company's financial position or operations. It reports a series of acquisitions of ordinary shares by six individuals (PDMRs and PCAs). All transactions were executed on the same date (April 9, 2020) at the same price (£15.3297).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The nature of all reported transactions is the acquisition of shares following the re-investment of dividends paid to shareholders on April 9, 2020.
Investor Verification Checklist
- Verify that the share price of £15.3297 aligns with the market price on April 9, 2020.
- Confirm the dividend payment date of April 9, 2020, to validate the reinvestment mechanism.
- Review the specific roles of the six individuals listed (Mr. N. Hirons, Ms. S. Jackson, Mr. D. Jackson, Ms. V. Whyte, Mr. I. Whyte, Ms. D. Connor) to ensure compliance with insider trading regulations.
- Note that this filing does not contain financial performance data; refer to the most recent Form 20-F or quarterly earnings release for revenue and profit metrics.